The purpose of this legislation is to make it easier for patients to access plasma-derived products, which are important medications made from human blood or plasma. The bill aims to gradually introduce a discount program for these products under Medicare, ensuring that they remain affordable for beneficiaries. Key provisions of the legislation include a phased-in discount structure for plasma-derived products starting in 2026. The discounts will be significant, beginning at 99 percent of the negotiated price for the first year and gradually decreasing over the following years.